Endometriosis Drugs Industry Research Report 2025
Description
Summary
According to APO Research, The global Endometriosis Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Endometriosis Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Endometriosis Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Endometriosis Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Endometriosis Drugs include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endometriosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endometriosis Drugs.The Endometriosis Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Endometriosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Endometriosis Drugs Segment by Company
Takeda Pharmaceutical Company Pfizer AbbVie AstraZeneca ValiRx Roivant Sciences Repros Therapeutics ObsEva Neurocrine Biosciences Kissei Pharmaceutical Evotec Debiopharm Group Astellas PharmaEndometriosis Drugs Segment by Type
Chinese Herbs Progestogens Hormonal Therapy Add-back MedicationEndometriosis Drugs Segment by Application
Research Institutes Hospitals ClinicsEndometriosis Drugs Segment by Application
Research Institutes Hospitals ClinicsEndometriosis Drugs Segment by Region
North America United States Canada Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Endometriosis Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Endometriosis Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Endometriosis Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Endometriosis Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Endometriosis Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Endometriosis Drugs include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endometriosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endometriosis Drugs.The Endometriosis Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Endometriosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Endometriosis Drugs Segment by Company
Takeda Pharmaceutical Company Pfizer AbbVie AstraZeneca ValiRx Roivant Sciences Repros Therapeutics ObsEva Neurocrine Biosciences Kissei Pharmaceutical Evotec Debiopharm Group Astellas PharmaEndometriosis Drugs Segment by Type
Chinese Herbs Progestogens Hormonal Therapy Add-back MedicationEndometriosis Drugs Segment by Application
Research Institutes Hospitals ClinicsEndometriosis Drugs Segment by Application
Research Institutes Hospitals ClinicsEndometriosis Drugs Segment by Region
North America United States Canada Europe Germany France U.K. Italy Spain Russia Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Saudi Arabia Israel United Arab Emirates Turkey Iran Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Endometriosis Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
115 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Endometriosis Drugs by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Chinese Herbs
- 2.2.3 Progestogens
- 2.2.4 Hormonal Therapy
- 2.2.5 Add-back Medication
- 2.3 Endometriosis Drugs by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Research Institutes
- 2.3.3 Hospitals
- 2.3.4 Clinics
- 2.4 Assumptions and Limitations
- 3 Endometriosis Drugs Breakdown Data by Type
- 3.1 Global Endometriosis Drugs Historic Market Size by Type (2020-2025)
- 3.2 Global Endometriosis Drugs Forecasted Market Size by Type (2026-2031)
- 4 Endometriosis Drugs Breakdown Data by Application
- 4.1 Global Endometriosis Drugs Historic Market Size by Application (2020-2025)
- 4.2 Global Endometriosis Drugs Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Endometriosis Drugs Market Perspective (2020-2031)
- 5.2 Global Endometriosis Drugs Growth Trends by Region
- 5.2.1 Global Endometriosis Drugs Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Endometriosis Drugs Historic Market Size by Region (2020-2025)
- 5.2.3 Endometriosis Drugs Forecasted Market Size by Region (2026-2031)
- 5.3 Endometriosis Drugs Market Dynamics
- 5.3.1 Endometriosis Drugs Industry Trends
- 5.3.2 Endometriosis Drugs Market Drivers
- 5.3.3 Endometriosis Drugs Market Challenges
- 5.3.4 Endometriosis Drugs Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Endometriosis Drugs Players by Revenue
- 6.1.1 Global Top Endometriosis Drugs Players by Revenue (2020-2025)
- 6.1.2 Global Endometriosis Drugs Revenue Market Share by Players (2020-2025)
- 6.2 Global Endometriosis Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Endometriosis Drugs Head Office and Area Served
- 6.4 Global Endometriosis Drugs Players, Product Type & Application
- 6.5 Global Endometriosis Drugs Manufacturers Established Date
- 6.6 Global Endometriosis Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Endometriosis Drugs Market Size (2020-2031)
- 7.2 North America Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Endometriosis Drugs Market Size by Country (2020-2025)
- 7.4 North America Endometriosis Drugs Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Endometriosis Drugs Market Size (2020-2031)
- 8.2 Europe Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Endometriosis Drugs Market Size by Country (2020-2025)
- 8.4 Europe Endometriosis Drugs Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Endometriosis Drugs Market Size (2020-2031)
- 9.2 Asia-Pacific Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Endometriosis Drugs Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Endometriosis Drugs Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Endometriosis Drugs Market Size (2020-2031)
- 10.2 South America Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Endometriosis Drugs Market Size by Country (2020-2025)
- 10.4 South America Endometriosis Drugs Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Endometriosis Drugs Market Size (2020-2031)
- 11.2 Middle East & Africa Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Endometriosis Drugs Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Endometriosis Drugs Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Takeda Pharmaceutical Company
- 12.1.1 Takeda Pharmaceutical Company Company Information
- 12.1.2 Takeda Pharmaceutical Company Business Overview
- 12.1.3 Takeda Pharmaceutical Company Revenue in Endometriosis Drugs Business (2020-2025)
- 12.1.4 Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
- 12.1.5 Takeda Pharmaceutical Company Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in Endometriosis Drugs Business (2020-2025)
- 12.2.4 Pfizer Endometriosis Drugs Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 AbbVie
- 12.3.1 AbbVie Company Information
- 12.3.2 AbbVie Business Overview
- 12.3.3 AbbVie Revenue in Endometriosis Drugs Business (2020-2025)
- 12.3.4 AbbVie Endometriosis Drugs Product Portfolio
- 12.3.5 AbbVie Recent Developments
- 12.4 AstraZeneca
- 12.4.1 AstraZeneca Company Information
- 12.4.2 AstraZeneca Business Overview
- 12.4.3 AstraZeneca Revenue in Endometriosis Drugs Business (2020-2025)
- 12.4.4 AstraZeneca Endometriosis Drugs Product Portfolio
- 12.4.5 AstraZeneca Recent Developments
- 12.5 ValiRx
- 12.5.1 ValiRx Company Information
- 12.5.2 ValiRx Business Overview
- 12.5.3 ValiRx Revenue in Endometriosis Drugs Business (2020-2025)
- 12.5.4 ValiRx Endometriosis Drugs Product Portfolio
- 12.5.5 ValiRx Recent Developments
- 12.6 Roivant Sciences
- 12.6.1 Roivant Sciences Company Information
- 12.6.2 Roivant Sciences Business Overview
- 12.6.3 Roivant Sciences Revenue in Endometriosis Drugs Business (2020-2025)
- 12.6.4 Roivant Sciences Endometriosis Drugs Product Portfolio
- 12.6.5 Roivant Sciences Recent Developments
- 12.7 Repros Therapeutics
- 12.7.1 Repros Therapeutics Company Information
- 12.7.2 Repros Therapeutics Business Overview
- 12.7.3 Repros Therapeutics Revenue in Endometriosis Drugs Business (2020-2025)
- 12.7.4 Repros Therapeutics Endometriosis Drugs Product Portfolio
- 12.7.5 Repros Therapeutics Recent Developments
- 12.8 ObsEva
- 12.8.1 ObsEva Company Information
- 12.8.2 ObsEva Business Overview
- 12.8.3 ObsEva Revenue in Endometriosis Drugs Business (2020-2025)
- 12.8.4 ObsEva Endometriosis Drugs Product Portfolio
- 12.8.5 ObsEva Recent Developments
- 12.9 Neurocrine Biosciences
- 12.9.1 Neurocrine Biosciences Company Information
- 12.9.2 Neurocrine Biosciences Business Overview
- 12.9.3 Neurocrine Biosciences Revenue in Endometriosis Drugs Business (2020-2025)
- 12.9.4 Neurocrine Biosciences Endometriosis Drugs Product Portfolio
- 12.9.5 Neurocrine Biosciences Recent Developments
- 12.10 Kissei Pharmaceutical
- 12.10.1 Kissei Pharmaceutical Company Information
- 12.10.2 Kissei Pharmaceutical Business Overview
- 12.10.3 Kissei Pharmaceutical Revenue in Endometriosis Drugs Business (2020-2025)
- 12.10.4 Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
- 12.10.5 Kissei Pharmaceutical Recent Developments
- 12.11 Evotec
- 12.11.1 Evotec Company Information
- 12.11.2 Evotec Business Overview
- 12.11.3 Evotec Revenue in Endometriosis Drugs Business (2020-2025)
- 12.11.4 Evotec Endometriosis Drugs Product Portfolio
- 12.11.5 Evotec Recent Developments
- 12.12 Debiopharm Group
- 12.12.1 Debiopharm Group Company Information
- 12.12.2 Debiopharm Group Business Overview
- 12.12.3 Debiopharm Group Revenue in Endometriosis Drugs Business (2020-2025)
- 12.12.4 Debiopharm Group Endometriosis Drugs Product Portfolio
- 12.12.5 Debiopharm Group Recent Developments
- 12.13 Astellas Pharma
- 12.13.1 Astellas Pharma Company Information
- 12.13.2 Astellas Pharma Business Overview
- 12.13.3 Astellas Pharma Revenue in Endometriosis Drugs Business (2020-2025)
- 12.13.4 Astellas Pharma Endometriosis Drugs Product Portfolio
- 12.13.5 Astellas Pharma Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Endometriosis Drugs Market Size by Type (2020-2025) & (US$ Million)
- Table 6. Global Endometriosis Drugs Revenue Market Share by Type (2020-2025)
- Table 7. Global Endometriosis Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
- Table 8. Global Endometriosis Drugs Revenue Market Share by Type (2026-2031)
- Table 9. Global Endometriosis Drugs Market Size by Application (2020-2025) & (US$ Million)
- Table 10. Global Endometriosis Drugs Revenue Market Share by Application (2020-2025)
- Table 11. Global Endometriosis Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
- Table 12. Global Endometriosis Drugs Revenue Market Share by Application (2026-2031)
- Table 13. Global Endometriosis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 14. Global Endometriosis Drugs Market Size by Region (2020-2025) & (US$ Million)
- Table 15. Global Endometriosis Drugs Market Share by Region (2020-2025)
- Table 16. Global Endometriosis Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
- Table 17. Global Endometriosis Drugs Market Share by Region (2026-2031)
- Table 18. Endometriosis Drugs Industry Trends
- Table 19. Endometriosis Drugs Industry Drivers
- Table 20. Endometriosis Drugs Industry Opportunities and Challenges
- Table 21. Endometriosis Drugs Market Restraints
- Table 22. Global Top Endometriosis Drugs Players by Revenue (US$ Million) & (2020-2025)
- Table 23. Global Endometriosis Drugs Revenue Market Share by Players (2020-2025)
- Table 24. Global Endometriosis Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- Table 25. Global Key Players of Endometriosis Drugs, Headquarters and Area Served
- Table 26. Global Endometriosis Drugs Players, Product Type & Application
- Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Endometriosis Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 29. Players Mergers & Acquisitions, Expansion Plans
- Table 30. North America Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 31. North America Endometriosis Drugs Market Size by Country (2020-2025) & (US$ Million)
- Table 32. North America Endometriosis Drugs Market Size by Country (2026-2031) & (US$ Million)
- Table 33. Europe Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 34. Europe Endometriosis Drugs Market Size by Country (2020-2025) & (US$ Million)
- Table 35. Europe Endometriosis Drugs Market Size by Country (2026-2031) & (US$ Million)
- Table 36. Asia Pacific Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 37. Asia Pacific Endometriosis Drugs Market Size by Region (2020-2025) & (US$ Million)
- Table 38. Asia Pacific Endometriosis Drugs Market Size by Country (2026-2031) & (US$ Million)
- Table 39. South America Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 40. South America Endometriosis Drugs Market Size by Country (2020-2025) & (US$ Million)
- Table 41. South America Endometriosis Drugs Market Size by Country (2026-2031) & (US$ Million)
- Table 42. Middle East & Africa Endometriosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 43. Middle East & Africa Endometriosis Drugs Market Size by Country (2020-2025) & (US$ Million)
- Table 44. Middle East & Africa Endometriosis Drugs Market Size by Country (2026-2031) & (US$ Million)
- Table 45. Takeda Pharmaceutical Company Company Information
- Table 46. Takeda Pharmaceutical Company Business Overview
- Table 47. Takeda Pharmaceutical Company Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 48. Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
- Table 49. Takeda Pharmaceutical Company Recent Developments
- Table 50. Pfizer Company Information
- Table 51. Pfizer Business Overview
- Table 52. Pfizer Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 53. Pfizer Endometriosis Drugs Product Portfolio
- Table 54. Pfizer Recent Developments
- Table 55. AbbVie Company Information
- Table 56. AbbVie Business Overview
- Table 57. AbbVie Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 58. AbbVie Endometriosis Drugs Product Portfolio
- Table 59. AbbVie Recent Developments
- Table 60. AstraZeneca Company Information
- Table 61. AstraZeneca Business Overview
- Table 62. AstraZeneca Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 63. AstraZeneca Endometriosis Drugs Product Portfolio
- Table 64. AstraZeneca Recent Developments
- Table 65. ValiRx Company Information
- Table 66. ValiRx Business Overview
- Table 67. ValiRx Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 68. ValiRx Endometriosis Drugs Product Portfolio
- Table 69. ValiRx Recent Developments
- Table 70. Roivant Sciences Company Information
- Table 71. Roivant Sciences Business Overview
- Table 72. Roivant Sciences Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 73. Roivant Sciences Endometriosis Drugs Product Portfolio
- Table 74. Roivant Sciences Recent Developments
- Table 75. Repros Therapeutics Company Information
- Table 76. Repros Therapeutics Business Overview
- Table 77. Repros Therapeutics Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 78. Repros Therapeutics Endometriosis Drugs Product Portfolio
- Table 79. Repros Therapeutics Recent Developments
- Table 80. ObsEva Company Information
- Table 81. ObsEva Business Overview
- Table 82. ObsEva Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 83. ObsEva Endometriosis Drugs Product Portfolio
- Table 84. ObsEva Recent Developments
- Table 85. Neurocrine Biosciences Company Information
- Table 86. Neurocrine Biosciences Business Overview
- Table 87. Neurocrine Biosciences Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 88. Neurocrine Biosciences Endometriosis Drugs Product Portfolio
- Table 89. Neurocrine Biosciences Recent Developments
- Table 90. Kissei Pharmaceutical Company Information
- Table 91. Kissei Pharmaceutical Business Overview
- Table 92. Kissei Pharmaceutical Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 93. Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
- Table 94. Kissei Pharmaceutical Recent Developments
- Table 95. Evotec Company Information
- Table 96. Evotec Business Overview
- Table 97. Evotec Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 98. Evotec Endometriosis Drugs Product Portfolio
- Table 99. Evotec Recent Developments
- Table 100. Debiopharm Group Company Information
- Table 101. Debiopharm Group Business Overview
- Table 102. Debiopharm Group Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 103. Debiopharm Group Endometriosis Drugs Product Portfolio
- Table 104. Debiopharm Group Recent Developments
- Table 105. Astellas Pharma Company Information
- Table 106. Astellas Pharma Business Overview
- Table 107. Astellas Pharma Revenue in Endometriosis Drugs Business (2020-2025) & (US$ Million)
- Table 108. Astellas Pharma Endometriosis Drugs Product Portfolio
- Table 109. Astellas Pharma Recent Developments
- Table 110. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Endometriosis Drugs Product Image
- Figure 5. Global Endometriosis Drugs Market Size Comparison by Type (2025-2031) & (US$ Million)
- Figure 6. Global Endometriosis Drugs Market Share by Type: 2024 VS 2031
- Figure 7. Chinese Herbs Product
- Figure 8. Progestogens Product
- Figure 9. Hormonal Therapy Product
- Figure 10. Add-back Medication Product
- Figure 11. Global Endometriosis Drugs Market Size by Application (2025-2031) & (US$ Million)
- Figure 12. Global Endometriosis Drugs Market Share by Application: 2024 VS 2031
- Figure 13. Research Institutes Product
- Figure 14. Hospitals Product
- Figure 15. Clinics Product
- Figure 16. Global Endometriosis Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
- Figure 17. Global Endometriosis Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
- Figure 18. Global Endometriosis Drugs Market Share by Region: 2024 VS 2031
- Figure 19. Global Endometriosis Drugs Market Share by Players in 2024
- Figure 20. Global Endometriosis Drugs Manufacturers Established Date
- Figure 21. Global Top 5 and 10 Endometriosis Drugs Players Market Share by Revenue in 2024
- Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 23. North America Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 24. North America Endometriosis Drugs Market Share by Country (2020-2031)
- Figure 25. United States Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 26. Canada Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 27. Mexico Endometriosis Drugs Market Share by Country (2020-2031)
- Figure 28. Europe Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 29. Europe Endometriosis Drugs Market Share by Country (2020-2031)
- Figure 30. Germany Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 31. France Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 32. U.K. Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 33. Italy Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 34. Spain Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 35. Russia Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 36. Netherlands Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 37. Nordic Countries Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 38. Asia-Pacific Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 39. Asia-Pacific Endometriosis Drugs Market Share by Country (2020-2031)
- Figure 40. China Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 41. Japan Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 42. South Korea Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 43. India Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 44. India Endometriosis Drugs Market Share by Country (2020-2031)
- Figure 45. Australia Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 46. China Taiwan Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 47. Southeast Asia Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 48. South America Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 49. South America Endometriosis Drugs Market Share by Country (2020-2031)
- Figure 50. Brazil Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 51. Argentina Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 52. Chile Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 53. Colombia Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 54. Peru Endometriosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 55. Takeda Pharmaceutical Company Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 56. Pfizer Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 57. AbbVie Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 58. AstraZeneca Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 59. ValiRx Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 60. Roivant Sciences Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 61. Repros Therapeutics Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 62. ObsEva Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 63. Neurocrine Biosciences Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 64. Kissei Pharmaceutical Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 65. Evotec Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 66. Debiopharm Group Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
- Figure 67. Astellas Pharma Revenue Growth Rate in Endometriosis Drugs Business (2020-2025)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


